|
Wednesday, March 29, 2006
Today, the Northern Cancer Research Foundation (NCRF) granted
$215,000 to a research scientist in the Cancer Care wet lab
at the Thunder Bay Regional Health Sciences Centre (TBRHSC).
 |
Dedicated completely to Northwestern Ontario, the
NCRF provides funding to improve the research and successful
collaborations with other leading centres, treatment,
and patient education and awareness. With the grants
provided, the cancer program can enhance service through
new treatment and diagnostic equipment, and create social
marketing campaigns to increase awareness around diseases
like colorectal and prostate cancer. “In the more
than ten years since the NCRF was created, the cancer
research program has grown exponentially,” said
Glenn Craig, President and CEO of the NCRF. “We
provided the initial funding for the research wet lab
at the cancer centre in 1997, stimulating the interest
and activity in cancer research in our region. This
growth has enabled us to attract the calibre of scientists
like Dr. Zehbe. We are pleased to contribute $215,000
towards her research, in hopes that it brings her team
closer to their goals.” |
 |
Dr. Ingeborg Zehbe joined the cancer centre research
team nearly a year ago from Mainz, Germany, where she
had developed an area of expertise in the field of tumour
biology. Her primary focus falls to the study of the
Human Papilloma Virus (HPV), the prime risk factor in
cervical cancer. She, along with her local co-authors
Dr. Nick Escott, and Dr. Glen Holloway, at the Thunder
Bay Regional Health Sciences Centre (TBRHSC) are concentrating
on studying cervical cancer caused by HPV. One of the
bases of their study is that a strong immune system
is essential to fight micro-organisms, disease, and
cancer. Taking it a step further, they are focusing
their study on the production of a type of proteins,
called cytokines, in women who are treated for abnormal
PAP smears. “My focus has been on HPV for a number
of years now,” stated Dr. Zehbe. “With this
funding from the NCRF, we have begun a control group
of blood samples from women attending the colposcopy
lab under the care of Dr. Holloway and Dr. Escott. With
these contributing results, we can determine, with all
factors equal, why some women develop cervical cancer
and some do not.” |
The proteins, or cytokines, are vital for the woman’s
immune system in helping specialized white blood cells to
fight transformed cells before they develop from “pre-cancerous”
into cancer. The ultimate goal of the research project is
to measure cytokines in women with “pre-cancer”
to determine if something is amiss with their immune system.
The study hypothesizes that women with a well functioning
immune system are more able to fight cervical cancer than
women whose immune system is impaired. They expect to be able
to apply this to the study and diagnosis of other tumour types,
using the knowledge obtained from this study to improve prognosis
and cancer therapy, specifically within immune therapy. Immune
therapy is an individual form of cancer treatment using cells
from the tumour patient which are “remodelled”
or “engineered” outside the body (“ex vivo”)
and thereafter donated back to the patient to perform tumour-killing
actions.
Dr. Zehbe holds the distinction of being the first member
of ICR Discoveries, the cancer research initiative in Northwestern
Ontario and collaboration between TBRHSC, Lakehead University,
and the Northern Ontario School of Medicine.
 |
ICR Discoveries is only one of the partnerships
that the cancer centre and TBRHSC continues to establish
and pursue. In the past few years, provincial, national,
and global partnerships have been established and proposed,
with most evolving through the research pillar of the
cancer program. “Our research program continues
to explore unique opportunities for teaching, research,
and education; especially in light of the way our system
is changing the way we treat people,” said Michael
Power, Vice President of Regional Cancer and Diagnostics.
“Over the last five years, our research scientists
have secured nearly five million dollars in local and
national grant funding, establishing a distinct foundation
for cancer research growth and development.” |
The NCRF and Regional Cancer Care are very pleased to be
leading this announcement into April, which is Cancer Awareness
Month. There are numerous activities designed to educate,
generate awareness, promote research, and provide information
on treatment and activity at Regional Cancer Care. Look for
the flags flying, the commercials, the newspaper, and keep
an eye out for the activities for the community to participate
in all month long. As always, and as further exemplified by
today’s announcement, all funds raised by the NCRF are
100% dedicated to supporting excellence in cancer care in
Northwestern Ontario.
Dr.
Ingeborg Zehbe Research Summary
Cancer
Research Overview
::
back to Media Releases ::
|
|